Antioxidants as treatment for neurodegenerative disorders

Bibliography

• MARKESBERY WR, CARNEY JM: Oxidative alterations in Alzheimer's disease. Brain Pathol (1999) 9:133–146.
   PubMed Web of Science ®Google Scholar
• JOSEPH J, SHUKITT-HALE B, DENISOVA NA, MARTIN A, PERRY G, SMITH MA: Copernicus revisited: amyloid 13 in Alzheimer's disease. Neurobiol. Aging (2001) 22:131–146.
   PubMed Web of Science ®Google Scholar
• •An interesting review to rearrange some old facts in AD: AP, ageing and oxidative stress.
   Google Scholar
• ZHANG Y, DAWSON VL, DAWSON TM: Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. (2000) 7:240–250.
   PubMed Web of Science ®Google Scholar
• FOLEY P, RIEDERER P: Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. Neurol (2000) 247\(Suppl. 2):II82-II94.
   Google Scholar
• BROWNE SE, FERRANTE RJ, BEAL MF: Oxidative stress in Huntington's disease. Brazil Pathol (1999) 9:147–163.
   PubMed Web of Science ®Google Scholar
• COOKSON MR, SHAW PJ: Oxidative stress and motor neurone disease. Brain Pathol (1999) 9:165–186.
   PubMed Web of Science ®Google Scholar
• SAYRE LM, SMITH MA, PERRY G: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curt Med. Chem. (2001) 8:721–738.
   PubMed Web of Science ®Google Scholar
• GIASSON BI, DUDA JE, MURRAY I et al.: Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science (2000) 290:985–989.
   PubMed Web of Science ®Google Scholar
• PAXINOU E, CHEN Q, WEISSE M et al.:Induction of a-synuclein aggregation by intracellular nitrative insult. J. Neurosci. (2001) 21:8053–8061.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MS, LANSBURY PT: Is there a cause-and-effect relationship between a-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. (2000) 2:E115–E119.
   Web of Science ®Google Scholar
• PERRY G, AVILA J, ESPEY MG, WINK DA, ATWOOD CS, SMITH MA: Biochemistry of neurodegeneration. Science (2001) 291:595–596.
   PubMed Web of Science ®Google Scholar
• SMITH MA, HARRIS PL, SAYRE LM, BECKMAN JS, PERRY G: Widespread peroxynitrite-mediated damage in Alzheimer's disease.' Neurosci. (1997) 17:2653–2657.
   PubMed Web of Science ®Google Scholar
• WALSH DM, HARTLEY DM, KUSUMOTO Y et al: Amyloid 13-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. Biol. Chem. (1999) 274:25945–25952.
   PubMed Web of Science ®Google Scholar
• HEAD E, GARZON-RODRIGUEZ W, JOHNSON JK, LOTT IT, COTMAN CW, GLABE C: Oxidation of A13 and plaque biogenesis in Alzheimer's disease and Down's syndrome. Neurobiol Dis. (2001) 8:792–806.
   PubMed Web of Science ®Google Scholar
• SCHWEERS 0, MANDELKOW EM, BIERNAT J, MANDELKOW E: Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. USA (1995) 92:8463–8467.
   PubMed Web of Science ®Google Scholar
• LOVELL MA, XIE C, MARKESBERYWR: Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging (2001) 22: 187–194.
   PubMed Web of Science ®Google Scholar
• FROST MT, HALLIWELL B, MOORE KP: Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/mass spectrometry method that avoids nitration artifacts. Biochem. (2000) 345:453–458.
   Google Scholar
• HALLIWELL B: Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res. (1999) 443:37–52.
   Google Scholar
• NUNOMURA A, PERRY G, PAPPOLLA MA et al.: Neuronal oxidative stress precedes amyloid-I3 deposition in Down's syndrome. Neuropathol Exp. Nemo]. (2000) 59:1011–1017.
   PubMed Web of Science ®Google Scholar
• PRATICO D, URYU K, LEIGHT S, TROJANOSWKI JQ, LEE VM: Increased lipid perwddation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. Neurosci. (2001) 21:4183–4187.
   PubMed Web of Science ®Google Scholar
• BETARBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. (2000) 3:1301–1306.
   PubMed Web of Science ®Google Scholar
• KOWALL NW, HANTRAYE P, BROUILLET E, BEAL ME MCKEE AC, FERRANTE RJ: MPTP induces a-synuclein aggregation in the substantia nigra of baboons. Neuroreport (2000) 11:211–213.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, ANDREASSEN OA, JENKINS BG et al.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease." Neurosci. (2000) 20: 4389–4397.
   Google Scholar
• HARMAN D: Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging (1993) 3:60–80.
   Google Scholar
• HARMAN D: Extending the functional life span. Exp. Gerontol. (1998) 33:95–112.
   PubMed Web of Science ®Google Scholar
• BECKMAN KB, AMES BN: The free radical theory of aging matures. Physiol. Rev (1998) 78:547–581.
   PubMed Web of Science ®Google Scholar
• •The state-of-the-art on the free radical theory of ageing.
   Google Scholar
• MARTIN GM, AUSTAD SN, JOHNSON TE: Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat. Genet. (1996) 13:25–34.
   PubMed Web of Science ®Google Scholar
• HARMAN D: A hypothesis on the pathogenesis of Alzheimer's disease. Ann. NY Acad. Sci. (1996) 786:152–168.
   PubMed Web of Science ®Google Scholar
• SIES H: Strategies of antioxidant defense. Eur.j Biochem. (1993) 215:213–219.
   PubMedGoogle Scholar
• BENDER E, KADENBACH B: The allosteric ATP-inhibition of cytochrome c coddase activity is reversibly switched on by cAMP-dependent phosphorylation. FEBS Lett. (2000) 466:130–134.
   PubMed Web of Science ®Google Scholar
• KADENBACH B, HUTTEMANN M, ARNOLD S, LEE I, BENDER E: Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic. Biol. Med. (2000) 29:211–221.
   PubMed Web of Science ®Google Scholar
• AMES BN: Micronutrients prevent cancer and delay aging. Toxicol. Lett. (1998) 102–103:5–18.
   Google Scholar
• •A focus on the importance of metabolic antioxidants.
   Google Scholar
• BOVERIS A, CHANCE B: The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. (1973) 134:707–716.
   Google Scholar
• BOVERIS A, CADENAS E: Mitochondrial production of hydrogen peroxide: regulation by nitric oxide and the role of ubisemiquinone. IUBMB Life (2000) 50:245–250.
   PubMed Web of Science ®Google Scholar
• SHIINO A, MATSUDA M, HANDA J, CHANCE B: Poor recovery of mitochondrial redox state in CA1 after transient forebrain ischemia in gerbils. Stroke (1998) 29:2421–2424.
   PubMed Web of Science ®Google Scholar
• WALLACE DC: A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found Symp. (2001) 235:247–263.
   PubMedGoogle Scholar
• BEAL MF: Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta (1998) 1366:211–223.
   PubMed Web of Science ®Google Scholar
• CASSARINO DS, BENNETT JP: An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Brain Res. Rev (1999) 29:1–25.
   PubMed Web of Science ®Google Scholar
• NICOTERA P, LIPTON SA: Excitotoxins in neuronal apoptosis and necrosis." Cereb. Blood Flow Metab. (1999) 19:583–591.
   PubMed Web of Science ®Google Scholar
• FLOYD RA: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. (1999) 222:236–245.
   PubMed Web of Science ®Google Scholar
• ATAMNA H, PALER-MARTINEZ A, AMES BN: N-t-Butyl hydroxylamine, a hydrolysis product of a-phenyl N t butyl nitrone, is more potent in delaying senescence in human lung fibroblasts. Biol. Chem. (2000) 275:6741–6748.
   Web of Science ®Google Scholar
• ATAMNA H, ROBINSON C, INGERSOLL R, ELLIOTT H, AMES BN: N-t-Butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro. FASEB (2001) 15:2196–2204.
   PubMed Web of Science ®Google Scholar
• GLENNER GG, WONG CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120:885–890.
   PubMed Web of Science ®Google Scholar
• MASTERS CL, SIMMS G, WEINMAN NA, MULTHAUP G, MCDONALD BL, BEYREUTHER K: Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl. Acad. Sci. USA (1985) 82:4245–4249.
   PubMed Web of Science ®Google Scholar
• KOSIK KS, JOACHIM CL, SELKOE DJ: Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer's disease. Proc. Nati Acad. Sci. USA (1986) 83:4044–4048.
   PubMed Web of Science ®Google Scholar
• STEINER H, HAASS C: Intramembrane proteolysis by presenilins. Nat. Rev Mol. Cell Biol. (2000) 1:217–224.
   PubMed Web of Science ®Google Scholar
• MAYEUX R, SAUNDERS AM, SHEA S et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl. J. Med. (1998) 338:506–511.
   PubMed Web of Science ®Google Scholar
• BEHL C: Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. (1999) 57:301–323.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(Suppl.):A23–A31.
   Google Scholar
• PRASAD KN, HOVLAND AR, COLE WC et al.: Multiple antioxidants in the prevention and treatment of Alzheimer's disease: analysis of biologic rationale. Clin. Neuropharmacol. (2000) 23:2–13.
   PubMed Web of Science ®Google Scholar
• CHRISTEN Y: Oxidative stress and Alzheimer's disease. Am. I Clin. Num. (2000) 71(Suppl.):621S–629S.
   Google Scholar
• NUNOMURA A, PERRY G, ALIEV G et al.: Cytosolic percoddative damage is an early event in Alzheimer's disease. I Neuropathol. Exp. Neurol. (2001) 60:759–767.
   PubMed Web of Science ®Google Scholar
• GALEAZZI L, RONCHI P, FRANCESCHI C, GIUNTA S: ha vitro percoddase oxidation induces stable dimers of 13-amyloid (1-42) through dityrosine bridge formation. Amyloid (1999) 6:7–13.
   PubMed Web of Science ®Google Scholar
• KOPPAKA V, AXELSEN PH: Accelerated accumulation of amyloid 13 proteins on coddatively damaged lipid membranes. Biochemistry (2000) 39:10011–10016.
   PubMed Web of Science ®Google Scholar
• PERUTZ ME WINDLE AH: Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature (2001) 412:143–144.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F 13-amyloid precursor protein. Nature (1995) 373:523–527.
   PubMed Web of Science ®Google Scholar
• STURCHLER-PIERRAT C, ABRAMOWSKI D, DUKE M et al: Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. Sci. USA (1997) 94:13287–13292.
   PubMed Web of Science ®Google Scholar
• HOLCOMB L, GORDON MN, MCGOWAN E et al.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4:97–100.
   PubMed Web of Science ®Google Scholar
• DEWACHTER I, VAN DORPE J, SPITTAELS K et al.: Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilinl on amyloid biochemistry and pathology in APP/London mice. Exp. Cerontol (2000) 35:831–841.
   PubMed Web of Science ®Google Scholar
• LEWIS J, DICKSON DW, UN WL et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 293:1487–1491.
   PubMed Web of Science ®Google Scholar
• FEZOUI Y, HARTLEY DM, HARPER JD et al.: An improved method of preparing the amyloid I3-protein for fibrillogenesis and neurotoxicity experiments. Amyloid (2000) 7:166–178.
   PubMed Web of Science ®Google Scholar
• BEHL C, DAVIS J, COLE GM, SCHUBERT D: Vitamin E protects nerve cells from amyloid 13 protein toxicity. Biochem. Biophys. Res. Commun. (1992) 186:944–952.
   PubMed Web of Science ®Google Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl. J. Med. (1997) 336:1216–1222.
   Google Scholar
• ••Pivotal clinical trial.
   Google Scholar
• GRUNDMAN M: Vitamin E and Alzheimer's disease: the basis for additional clinical trials. Am. Gin. Num (2000) 71(Suppl.):630S–636S.
   Google Scholar
• FILIP V, KOLIBAS E: Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. I Psychiatry Neurosci. (1999) 24:234–243.
   Google Scholar
• FREEDMAN M, REWILAK D, XERRI T et al.: L-Deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology (1998) 50:660–668.
   PubMed Web of Science ®Google Scholar
• ALAFUZOFF I, HELISALMI S, HEINONEN EH et al: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eui: Clin. Pharmacol (2000) 55:815–819.
   PubMed Web of Science ®Google Scholar
• THAL LJ, CALVANI M, AMATO A, CARTA A et al.: A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology (2000) 55:805–810.
   PubMed Web of Science ®Google Scholar
• ••The most recent clinical trial on carnitinein AD, which had an essentially negative outcome.
   Google Scholar
• THAL LJ, CARTA A, CLARKE WR et al.: A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology(1996) 47:705–711.
   PubMed Web of Science ®Google Scholar
• SPAGNOLI A, LUCCA U, MENASCE G et al.: Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology (1991) 41:1726–1732.
   PubMed Web of Science ®Google Scholar
• PETTEGREW JW, LEVINE J, MCCLURE RJ: Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Ma Psychiatry (2000) 5:616–632.
   Web of Science ®Google Scholar
• VIRMANI MA, CASO V, SPADONI A, ROSSI S, RUSSO F, GAETANI F: The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann. NY Acad. Li. (2001) 939:162–178.
   PubMed Web of Science ®Google Scholar
• GUTZMANN H, HADLER D: Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. I Neural Transm. Sapp]. (1998) 54:301–310.
   Google Scholar
• •Important clinical trial.
   Google Scholar
• WEYER G, BABEJ-DOLLE RIVI, HADLER D, HOFMANN S, HERRMANN WM: A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology (1997) 36:73–82.
   PubMed Web of Science ®Google Scholar
• YAMADA K, TANAKA T, HAN D, SENZAKI K, KAMEYAMA T, NABESHIMA T: Protective effects of idebenone and a-tocopherol on I3-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in I3-amyloid-induced neurotoxicity M vivo. Eur. NeuroscC (1999) 11:83–90.
   PubMed Web of Science ®Google Scholar
• HIRAI K, HAYAKO H, KATO K, MIYAMOTO M: Idebenone protects hippocampal neurons against amyloid 13-peptide-induced neurotoxicity in rat primary cultures. Naunyn Schmiedebergs Arch. Pharmacol (1998) 358:582–585.
   PubMed Web of Science ®Google Scholar
• ADAIR JC, KNOEFEL JE, MORGAN N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology (2001) 57:1515–1517.
   PubMed Web of Science ®Google Scholar
• •Interesting clinical trial.
   Google Scholar
• PAGANINI-HILL A, HENDERSON VW: Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. (1996) 156:2213–2217.
   PubMed Web of Science ®Google Scholar
• TANG MX, JACOBS D, STERN Y et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429–432.
   PubMed Web of Science ®Google Scholar
• WARING SC, ROCCA WA, PETERSEN RC et al.: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology (1999) 52:965–970.
   PubMed Web of Science ®Google Scholar
• CARLSON MC, ZANDI PP, PLASSMAN BL et al.: Hormone replacement therapy and reduced cognitive decline in older women: The Cache County Study. Neurology (2001) 57:2210–2216.
   PubMed Web of Science ®Google Scholar
• IN 'T VELD BA, RUITENBERG A, HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl. I Med. (2001) 345:1515–1521.
   Google Scholar
• •Unique in size and concept, this analysis concludes a pronounced protective effect of long-term NSAID use in AD.
   Google Scholar
• BREITNERJC, ZANDI PP: Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl. I Med. (2001) 345:1567–1568.
   Google Scholar
• ZANDI PP, BREITNER JC: Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging (2001) 22:811–817.
   PubMed Web of Science ®Google Scholar
• NOURHASHEMI F, GILLETTE-GUYONNET S, ANDRIEU S et al: Alzheimer's disease: protective factors. Am. Gin. Num (2000) 71(Suppl.):643S–649S.
   Google Scholar
• MCGEER PL, ROGERS J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology (1992) 42:447–449.
   PubMed Web of Science ®Google Scholar
• AKIYAMA H, BARGER S, BARNUM S et al.: Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21:383–421.
   PubMed Web of Science ®Google Scholar
• BEHL C, MOOSMANN B, MANTHEY D, HECK S: The female sex hormone oestrogen as neuroprotectant: activities at various levels. Novartis Found. Symp. (2000) 230:221–238.
   PubMedGoogle Scholar
• MCEWEN BS, ALVES SE: Estrogen actions in the central nervous system. Endocc Rev. (1999) 20:279–307.
   PubMed Web of Science ®Google Scholar
• BABIOR BM: Phagocytes and oxidative stress. Am. J. Med. (2000) 109:33–44.
   PubMed Web of Science ®Google Scholar
• HEWETT SJ, ULIASZ TF, VIDWANS AS, HEWETT JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. I Pharmacol Exp. Thec (2000) 293:417–425.
   PubMed Web of Science ®Google Scholar
• LI Y, MAHER P, SCHUBERT D: A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron (1997) 19:453–463.
   PubMed Web of Science ®Google Scholar
• MAFFEI FACINO R, CARINI M, ALDINI G, SAIBENE L, MACCIOCCHI A: Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int. .1. Tissue React. (1993) 15:225–234.
   PubMedGoogle Scholar
• LAMBAT Z, CONRAD N, ANOOPKUMAR-DUKIE S, WALKER RB, DAYA S: An investigation into the neuroprotective properties of ibuprofen. Metab. Brain Dis. (2000) 15:249–256.
   PubMed Web of Science ®Google Scholar
• WEGGEN S, ERIKSEN JL, DAS P et al: A subset of NSAIDs lower amyloidogenic Al342 independently of cyclooxygenase activity. Nature (2001) 414:212–216.
   PubMed Web of Science ®Google Scholar
• MOOSMANN B, BEHL C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl. Acad. Sci. USA (1999) 96:8867–8872.
   PubMed Web of Science ®Google Scholar
• OZDEN S, DILDAR K, KADIR YH, GULIZAR K: The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas (2001) 38:165–170.
   PubMed Web of Science ®Google Scholar
• LEAL M, DIAZ J, SERRANO E, ABELLAN J, CARBONELL LF: Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. ObsteL Gynecol. (2000) 95:804–809.
   PubMed Web of Science ®Google Scholar
• BHAVNANI BR, CECUTTI A, GERULATH A, WOOLEVER AC, BERCO M: Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause (2001) 8:408–419.
   PubMed Web of Science ®Google Scholar
• SHERWIN BB: Can estrogen keep you smart? Evidence from clinical studies. Psychiatry Neurosci. (1999) 24:315–321.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology (2000) 54:295–301.
   PubMed Web of Science ®Google Scholar
• WANG PN, LIAO SQ, LIU RS et al: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 54:2061–2066.
   PubMed Web of Science ®Google Scholar
• MULNARD RA, COTMAN CW, KAWAS C et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's disease Cooperative Study. JAMA (2000) 283:1007–1015.
   Web of Science ®Google Scholar
• ASTHANA S, BAKER LD, CRAFT S et al.: High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology(2001) 57:605–612.
   PubMed Web of Science ®Google Scholar
• SHERWIN BB: Oestrogen and cognitive function throughout the female lifespan. Novartis Found Symp. (2000) 230:188–201.
   PubMedGoogle Scholar
• AISEN PS, DAVIS KL, BERG JD et al: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease Cooperative Study. Neurology (2000) 54:588–593.
   Google Scholar
• SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTOPHIDIS N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53:197–201.
   PubMed Web of Science ®Google Scholar
• ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer's disease. Neurology(1993) 43:1609–1611.
   PubMed Web of Science ®Google Scholar
• VAN GOOL WA, WEINSTEIN HC, SCHELTENS PK, WALSTRA GJ: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 358:455–460.
   PubMed Web of Science ®Google Scholar
• HULL M, LIEB K, FIEBICH BL: Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin. Investig. Drugs (2000) 9:671–683.
   Web of Science ®Google Scholar
• REITER RJ, ACUNA-CASTROVIEJO D, TAN DX, BURKHARDT S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. NY Acad. Sci. (2001) 939:200–215.
   PubMed Web of Science ®Google Scholar
• PAPPOLLA MA, CHYAN YJ, POEGGELER B et al.: An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. I Neural Transm. (2000) 107:203–231.
   PubMed Web of Science ®Google Scholar
• POEGGELER B, MIRAVALLE L, ZAGORSKI MG et al.: Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid 13 peptide. Biochemistry (2001) 40:14995–15001.
   PubMed Web of Science ®Google Scholar
• CLAPP-LILLY KL, SMITH MA, PERRY G, HARRIS PL, ZHU X, DUFFY LK: Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. Neuroreport (2001) 12:1277–1280.
   PubMed Web of Science ®Google Scholar
• BRUSCO LI, MARQUEZ M, CARDINALI DP: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett. (2000) 21:39–42.
   PubMed Web of Science ®Google Scholar
• DEFEUDIS FV, DRIEU K: Gingko biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Can: Drug Targets (2000) 1:25–58.
   PubMedGoogle Scholar
• BASTIANETTO S, RAMASSAMY C, DORE S, CHRISTEN Y, POIRIER J, QUIRION R: The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by I3-amyloid. Eur. Neurosci. (2000) 12:1882–1890.
   PubMed Web of Science ®Google Scholar
• BASTIANETTO S, ZHENG WH, QUIRION R: The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. Neurochem. (2000) 74:2268–2277.
   PubMed Web of Science ®Google Scholar
• WATANABE CM, WOLFFRAM S, ADER P et al.: The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc. Natl Acad. Sci. USA (2001) 98:6577–6580.
   PubMed Web of Science ®Google Scholar
• OKEN BS, STORZBACH DM, KAYE JA: The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch. Neurol (1998) 55:1409–1415.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of clinical studies on Ginkgo in AD, concluding a modest, but significant beneficial role.
   Google Scholar
• KANOWSKI S, HERRMANN WM, STEPHAN K, WIERICH W, HORR R: Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry (1996) 29:47–56.
   PubMed Web of Science ®Google Scholar
• LE BARS PL, KATZ MM, BERMAN N, ITIL TM, FREEDMAN AM, SCHATZBERG AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA (1997) 278:1327–1332.
   PubMed Web of Science ®Google Scholar
• VAN DONGEN MC, VAN ROSSUM E, KESSELS AG, SIELHORST HJ, KNIPSCHILD PG: The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial." Am. Geriatr. Soc. (2000) 48:1183–1194.
   PubMed Web of Science ®Google Scholar
• •A recent clinical trial on Ginkgo in AD and vascular dementia, reporting the absence of any beneficial effect of this drug.
   Google Scholar
• LIM GP, CHU T, YANG F, BEECH W, FRAUTSCHY SA, COLE GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse." NeuroscL (2001) 21:8370–8377.
   PubMed Web of Science ®Google Scholar
• FRAUTSCHY SA, HU W, KIM P et al: Phenolic anti-inflammatory antioxidant reversal of AP-induced cognitive deficits and neuropathology. Neurobiol. Aging (2001) 22:993–1005.
   PubMed Web of Science ®Google Scholar
• CHERNY RA, ATWOOD CS, XILINAS ME et al.: Treatment with a copper-zinc chelator markedly and rapidly inhibits 13-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 30:665–676.
   PubMed Web of Science ®Google Scholar
• GOURAS GK, BEAL MF: Metal chelator decreases Alzheimer 3-amyloid plaques. Neuron (2001) 30:641–642.
   PubMed Web of Science ®Google Scholar
• SMITH MA, HARRIS PL, SAYRE LM, PERRY G: Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA (1997) 94:9866–9868.
   PubMed Web of Science ®Google Scholar
• HUANG X, CUAJUNGCO MP, ATWOOD CS et al.: Cu(II) potentiation of Alzheimer Ap neurotoxicity. Biol. Chem. (1999) 274:37111–37116.
   Web of Science ®Google Scholar
• CRAPPERMCLACHLAN DR, DALTON AJ, KRUCK TP et al.: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet (1991) 337:1304–1308.
   PubMed Web of Science ®Google Scholar
• MUNCH G, TANELI Y, SCHRAVEN E et al.: The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. Neural Transm. Park. Dis. Dement. Sect. (1994) 8:193–208.
   PubMedGoogle Scholar
• SHODA H, MIYATA S, LIU BF et al: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology (1997) 138:1886–1892.
   PubMed Web of Science ®Google Scholar
• BEHL C, DAVIES JB, LESLEY R, SCHUBERT D: Hydrogen peroxide mediates amyloid 13 protein toxicity. Cell (1994) 77:817–827.
   PubMed Web of Science ®Google Scholar
• BRUCE AJ, MALFROY B, BAUDRY M: P-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK- 8, a synthetic catalytic free radical scavenger. Proc. Nati Acad. Sci. USA (1996) 93:2312–2316.
   PubMed Web of Science ®Google Scholar
• BAKER K, MARCUS CB, HUFFMAN K, KRUK H, MALFROY B, DOCTROW SR: Synthetic combined superoxide dismutase/ catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. I Pharmacol. Exp. The]: (1998) 284:215–221.
   PubMed Web of Science ®Google Scholar
• MALFROY B, DOCTROW SR, ORR PL, TOCCO G, FED OSEYEVA EV, BENICHOU G: Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell. Immunol. (1997) 177:62–68.
   PubMed Web of Science ®Google Scholar
• CUZZOCREA S, RILEY DP, CAPUTI AP, SALVEMINI D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev (2001) 53:135–159.
   PubMed Web of Science ®Google Scholar
• RONG Y, DOCTROW SR, TOCCO G, BAUDRY M: EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. Nati Acad. Sci. USA (1999) 96:9897–9902.
   PubMed Web of Science ®Google Scholar
• LANG AE, LOZANO AM: Parkinson's disease. N Engl. J. Med. (1998) 339:1044–1153.
   PubMed Web of Science ®Google Scholar
• LANG AE, LOZANO AM: Parkinson's disease. N. Engl. J. Med. (1998) 339:1130–1143.
   PubMed Web of Science ®Google Scholar
• SHARON R, GOLDBERG MS, BAR-JOSEF I, BETENSKY RA, SHEN J, SELKOE DJ: a-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA (2001) 98:9110–9115.
   PubMed Web of Science ®Google Scholar
• ABELIOVICH A, SCHMITZ Y, FARINAS I et al.: Mice lacking a-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 25:239–252.
   PubMed Web of Science ®Google Scholar
• MASLIAH E, ROCKENSTEIN E, VEINBERGS I et al.: Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science (2000) 287:1265–1269.
   PubMed Web of Science ®Google Scholar
• VAN DER PUTTEN H, WIEDERHOLD KH, PROBST A et al.: Neuropathology in mice expressing human a-synuclein. I NeuroscL (2000) 20:6021–6029.
   Google Scholar
• TABRIZI SJ, ORTH M, WILKINSON JM et al.: Expression of mutant a-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. (2000) 9:2683–2689.
   PubMed Web of Science ®Google Scholar
• SOUZA JM, GIASSON BI, CHEN Q, LEE VM, ISCHIROPOULOS H: Dityrosine cross-linking promotes formation of stable a-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. ./. Biol. Chem. (2000) 275:18344–18349.
   Google Scholar
• CONWAY KA, ROCHET JC, BIEGANSKI RIVI, LANSBURY PT: Kinetic stabilization of the a-synuclein protofibril by a dopamine-a-synuclein adduct. Science (2001) 294:1346–1349.
   PubMed Web of Science ®Google Scholar
• SCOTT WK, NANCE MA, WATTS RL et al.: Complete genomic screen in Parkinson's disease: evidence for multiple genes. "AMA (2001) 286:2239–2244.
   Google Scholar
• SVEINBJORNSDOTTIR S, HICKS AA, JONSSON T et al.: Familial aggregation of Parkinson's disease in Iceland. N Engl. I Med. (2000) 343:1765–1770.
   PubMed Web of Science ®Google Scholar
• TANNER CM, OTTMAN R, GOLDMAN SM et al: Parkinson's disease in twins: an etiologic study. "AMA (1999) 281:341–346.
   PubMed Web of Science ®Google Scholar
• PAGANINI-HILL A: Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology (2001) 20:118–124.
   PubMed Web of Science ®Google Scholar
• ASCHERIO A, ZHANG SM, HERNAN MA et al.: Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Nemo]. (2001) 50:56–63.
   PubMed Web of Science ®Google Scholar
• ROSS GW, PETROVITCH H: Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging (2001) 18:797–806.
   PubMed Web of Science ®Google Scholar
• TUCHSEN F, JENSEN AA: Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. Scand. I Work Environ. Health (2000) 26:359–362.
   PubMed Web of Science ®Google Scholar
• BEHARI M, SRIVASTAVA AK, DAS RR, PANDEY RIVI: Risk factors of Parkinson's disease in Indian patients. J. Neurol. Sci. (2001) 190:49–55.
   PubMed Web of Science ®Google Scholar
• POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al.: Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science (1997) 276:2045–2047.
   PubMed Web of Science ®Google Scholar
• GASSER T: Genetics of Parkinson's disease. J. Nemo]. (2001) 248:833–840.
   Web of Science ®Google Scholar
• MENDIS T, SUCHOWERSKY 0, LANG A, GAUTHIER S: Management of Parkinson's disease. A review of current and new therapies. Can. I Nemo]. Sci. (1999) 26:89–103.
   Google Scholar
• FAHN S: Parkinson's disease, the effect of levodopa, and the ELLDOPA trial. Arch. Neurol (1999) 56:529–535.
   PubMed Web of Science ®Google Scholar
• ZESIEWICZ TA, HAUSER RA: Neurosurgery for Parkinson's disease. Semin. Neurol (2001) 21:91–101.
   PubMed Web of Science ®Google Scholar
• GERLACH M, RIEDERER P: Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. (1996) 103:987–1041.
   PubMed Web of Science ®Google Scholar
• BLUM B, TORCH S, LAMBENG Net al.: Molecular pathways involved in the neurotoxicity of 6–0HDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol (2001) 65:135–172.
   Google Scholar
• BEAL MF: Experimental models of Parkinson's disease. Nat. Rev Neurosci. (2001) 2:325–334.
   PubMed Web of Science ®Google Scholar
• LANGSTON JW, BALLARD P, TETRUD JW, IRWIN I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 219:979–980.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, BINDOKAS VP, MARKS JD et al: The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. MM. Pharmacol (2000) 58:271–278.
   PubMed Web of Science ®Google Scholar
• THOENEN H, TRANZER JP: Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn Schmiedebergs Arch. Exp. Pathol Pharmakol (1968) 261:271–288.
   PubMedGoogle Scholar
• BLOOM FE, ALGERI S, GROPPETTI A, REVUELTA A, COSTA E: Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science (1969) 166:1284–1286.
   PubMed Web of Science ®Google Scholar
• ANDREW R, WATSON DG, BEST SA, MIDGLEY JM, WENLONG H, PETTY RK: The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. (1993) 18:1175–1177.
   PubMed Web of Science ®Google Scholar
• SIMUNI T, STERN MB: Does levodopa accelerate Parkinson's disease? Drugs Aging (1999) 14:399–408.
   PubMed Web of Science ®Google Scholar
• LINERT W, HERLINGER E, JAMESON RF, KIENZL E, JELLINGER K, YOUDIM MB: Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta. (1996) 1316:160–168.
   PubMed Web of Science ®Google Scholar
• JELLINGER KA: The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging (1999) 14:115–140.
   PubMed Web of Science ®Google Scholar
• GLINKA Y, TIPTON KF, YOUDIM MB: Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur: Pharmacol (1998) 351:121–129.
   PubMed Web of Science ®Google Scholar
• DAVIDSON C, GOW AJ, LEE TH, ELLINWOOD EH: Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brad) Res. Rev (2001) 36:1–22.
   PubMed Web of Science ®Google Scholar
• XIA XG, SCHMIDT N, TEISMANN P, FERGER B, SCHULZ JB: Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. Neurochem. (2001) 79:63–70.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, WRIGHT DA, WIATR T et al.: Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin. I Neurochem. (2000) 74:2305–2314.
   PubMed Web of Science ®Google Scholar
• CHOI HJ, JANG YJ, KIM HJ, HWANG 0: Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Pharmacol (2000) 58:633–640.
   Web of Science ®Google Scholar
• KOTSONIS P, FROHLICH LG, SHUTENKO ZV, HOREJSI R, PFLEIDERER W, SCHMIDT HH: Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem. J. (2000) 346:767–776.
   PubMed Web of Science ®Google Scholar
• LI H, FORSTERMANN U: Nitric oxide in the pathogenesis of vascular disease." Pathol (2000) 190:244–254.
   PubMed Web of Science ®Google Scholar
• WEVER RIVI, VAN DAMT, VAN RIJN HJ, DE GROOT F, RABELINK TJ: Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem. Biophys. Res. Commun. (1997) 237:340–344.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J. Med. (1993) 328:176–183.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial reporting beneficialeffects of selegiline (deprenyl), but not tocopherol in PD.
   Google Scholar
• KIEBURTZ K, MCDERMOTT M, COMO P et al.: The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology (1994) 44:1756–1759.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol (1996) 40:99–107.
   PubMed Web of Science ®Google Scholar
• TETRUD JW, LANGSTON JW: The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 245:519–522.
   PubMed Web of Science ®Google Scholar
• BIRKMAYER W, KNOLL J, RIEDERER P, YOUDIM MB, HARSV, MARTON J: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. I. Neural Bansm. (1985) 64:113–127.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol (1996) 39:29–36.
   PubMed Web of Science ®Google Scholar
• ••Follow-up analysis of the DATATOPcohort implying that selegiline therapy is not sustainingly neuroprotective.
   Google Scholar
• PARKINSON STUDY GROUP: Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann. Neurol (1998) 43:318–325.
   PubMed Web of Science ®Google Scholar
• •Follow-up study reporting no differences in mortality between treatment groups.
   Google Scholar
• BEN-SHLOMO Y, CHURCHYARD A, HEAD J et al: Investigation by Parkinson's disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ(1998) 316:1191–1196.
   PubMed Web of Science ®Google Scholar
• DONNAN PT, STEINKE DT, STUBBINGS C, DAVEY PG, MACDONALD TM: Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology (2000) 55:1785–1789.
   PubMed Web of Science ®Google Scholar
• SHOULSON I, DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. 1429 Neurol (1998) 44\(Suppl. 1):S160–S166.
   Google Scholar
• •A review summarising the current opinion with respect to selegiline and tocopherol in PD.
   Google Scholar
• FAHN S: A pilot trial of high-dose a-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol (1992) 32(Suppl.):S128–132.
   Google Scholar
• PERRY TL, YONG VW, HANSEN S et al.: a-Tocopherol and 13-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Nemo] ScL (1987) 81:321–331.
   PubMed Web of Science ®Google Scholar
• MIHATSCH W, RUSS H, GERLACH M, RIEDERER P, PRZUNTEK H: Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. Neural Transm. Park. Dis. Dement. Sect. (1991) 3:73–78.
   PubMedGoogle Scholar
• ODUNZE IN, KLAIDMAN LK, ADAMS JD: MPTP toxicity in the mouse brain and vitamin E. Neurosci. Lett. (1990) 108:346–349.
   PubMed Web of Science ®Google Scholar
• DEXTER DT, BROOKS DJ, HARDING AE et al.: Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann. Neurol (1994) 35:298–303.
   PubMed Web of Science ®Google Scholar
• DEXTER DT, NANAYAKKARA I, GOSS-SAMPSON MA et al.: Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport (1994) 5:1773–1776.
   PubMed Web of Science ®Google Scholar
• DEXTER DT, WARD RJ, WELLS FR et al.: a-Tocopherol levels in brain are not altered in Parkinson's disease. Ann. Neurol (1992) 32:591–593.
   PubMed Web of Science ®Google Scholar
• VATASSERY GT, FAHN S, KUSKOWSKI MA: a-Tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson study group. Neurology(1998) 50:1900–1902.
   PubMed Web of Science ®Google Scholar
• •An interesting report on vitamin E and the human brain. It illustrates the poor permeation of the BBB by vitamin E.
   Google Scholar
• SCHAPIRA AH, COOPER JM, DEXTER D, CLARK JB, JENNER P, MARSDEN CD: Mitochondrial complex I deficiency in Parkinson's disease.' Neurochem. (1990) 54:823–827.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA AH, MANN VM, COOPER JM et al.: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. j. Neurochem. (1990) 55:2142–2145.
   PubMed Web of Science ®Google Scholar
• SHOFFNER JM, WATTS RL, JUNCOS JL, TORRONI A, WALLACE DC: Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol (1991) 30:332–339.
   PubMed Web of Science ®Google Scholar
• SIMON DK, MAYEUX R, MARDER K, KOWALL NW, BEAL ME JOHNS DR: Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology (2000) 54:703–709.
   PubMed Web of Science ®Google Scholar
• SHULTS CW, HAAS RH, PASSOV D, BEAL MF: Coenzyme Q10 levels correlate with the activities of complexes I and in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Nemo] (1997) 42:261–264.
   PubMed Web of Science ®Google Scholar
• GOTZ ME, GERSTNER A, HARTH R et al.: Altered redox state of platelet coenzyme Q10 in Parkinson's disease. j. Neural Transm. (2000) 107:41–48.
   PubMed Web of Science ®Google Scholar
• SCHULZ JB, HENSHAW DR, MATTHEWS RT, BEAL MF: Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol (1995) 132:279–283.
   PubMed Web of Science ®Google Scholar
• FALLON J, MATTHEWS RT, HYMAN BT, BEAL MF: MPP±produces progressive neuronal degeneration which is mediated by oxidative stress. Exp. Nemo] (1997) 144:193–198.
   PubMed Web of Science ®Google Scholar
• BEAL ME MATTHEWS RT, TIELEMAN A, SHULTS CW: Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. (1998) 783:109–114.
   PubMed Web of Science ®Google Scholar
• MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL MF: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Nat] Acad. Sci. USA (1998) 95:8892–8897.
   PubMed Web of Science ®Google Scholar
• STRIJKS E, KREMER HP, HORSTINK MW: Q10 therapy in patients with idiopathic Parkinson's disease. Ma Aspects Med. (1997) 18(Suppl.):S237–240.
   Google Scholar
• SHULTS CW, BEAL MF, FONTAINE D, NAKANO K, HAAS RH: Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology (1998) 50:793-795. MAYEUX R, MARDER K, COTE LJ et al.: The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am. j Epidemiol (1995) 142:820-827. BALDERESCHI M, DI CARLO A, ROCCA WA et al.: Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology (2000) 55:1358–1363.
   Google Scholar
• MARDER K, TANG MX, ALFARO B et al.: Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology (1998) 50:1141–1143.
   PubMed Web of Science ®Google Scholar
• SAUNDERS-PULLMAN R, GORDON-ELLIOTT J, PARIDES M, FAHN S, SAUNDERS HR, BRESSMAN S: The effect of estrogen replacement on early Parkinson's disease. Neurology (1999) 52:1417–1421.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ HH, LAPANE KL: Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Mov. Disord. (2000) 15:1119–1124.
   PubMed Web of Science ®Google Scholar
• BLANCHET PJ, FANG J, HYLAND K, ARNOLD LA, MOURADIAN MM, CHASE TN: Short-term effects of high-dose 1713-estradiol in postmenopausal PD patients: a crossover study. Neurology(1999) 53:91–95.
   PubMed Web of Science ®Google Scholar
• TSANG KL, HO SL, LO SK: Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology (2000) 54:2292–2298.
   PubMed Web of Science ®Google Scholar
• LERANTH C, ROTH RH, ELSWORTH JD, NAFTOLIN F, HORVATH TL, REDMOND DE: Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. I NeuroscL (2000) 20:8604–8609.
   PubMed Web of Science ®Google Scholar
• MILLER DB, ALI SF, O'CALLAGHAN JP, LAWS SC: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. NY Acad. Sci. (1998) 844:153–165.
   PubMed Web of Science ®Google Scholar
• EBADI M, GOVITRAPONG P,213. SHARIVIA S et al.: Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. (2001) 10:224–253.
   Google Scholar
• LENAZ G: A critical appraisal of the214.mitochondrial coenzyme Q pool. FEBS Lett. (2001) 509:151–155.
   Google Scholar
• JIMENEZ-JIMENEZ FJ, MOLINA JA, DE BUSTOS F et al: Serum levels of coenzyme Q10 in patients with Parkinson's disease. Neural Transm. (2000) 107:177-215.181.
   Google Scholar
• CALLIER S, MORISSETTE M, GRANDBOIS M, PELAPRAT D, DI PAOLO T: Neuroprotective properties of 1713-estradiol, progesterone, and raloxifene in MPTP C57B1/6 mice. Synapse (2001) 41:131–138.
   PubMed Web of Science ®Google Scholar
• TARNOPOLSKY MA, MARTIN J: Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology (1999) 52:854–857.
   PubMed Web of Science ®Google Scholar
• TARNOPOLSKY MA, BEAL MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. (2001) 49:561–574.
   PubMed Web of Science ®Google Scholar
• •The state-of-the-art on metabolic stabilisers in neurological disease.
   Google Scholar
• MATTHEWS RT, FERRANTE RJ, KLIVENYI P et al.: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. (1999) 157:142–149.
   PubMed Web of Science ®Google Scholar
• HANTRAYE P, BROUILLET E, FERRANTE R et al.: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. (1996) 2:1017–1021.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, HANTRAYE P, BROUILLET E, BEAL MF: Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. (1999) 823:177–182.
   PubMed Web of Science ®Google Scholar
• IMAM SZ, CROW JP, NEWPORT GD, ISLAM F, SLIKKER W, ALI SF: Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. (1999) 837:15–21.
   PubMed Web of Science ®Google Scholar
• SALVEMINI D, WANG ZQ, STERN MK, CURRIE MG, MISKO TP: Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc. Nati Acad. Sri. USA(1998) 95:2659–2663.
   PubMed Web of Science ®Google Scholar
• IMAM SZ, EL-YAZAL J, NEWPORT GD et al.: Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. NY Acad. Sci. (2001) 939:366–380.
   PubMed Web of Science ®Google Scholar
• PARNHAM M, SIES H: Ebselen: prospective therapy for cerebral ischaemia. Expert Opin. Investig. Drugs (2000) 9:607–619.
   PubMed Web of Science ®Google Scholar
• MASUMOTO H, SIES H. The reaction of 2- (methylseleno)benzanilide with peroxynitrite. Chem. Res. Toxicol. (1996) 9:1057–1062.
   PubMed Web of Science ®Google Scholar
• MOUSSAOUI S, OBINU MC, DANIEL N, REIBAUD M, BLANCHARD V, IMPERATO A: The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. (2000) 166:235–245.
   PubMed Web of Science ®Google Scholar
• MATTHEWS RT, KLIVENYI P, MUELLER G et al.: Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol. (1999) 157:120–126.
   PubMed Web of Science ®Google Scholar
• KARLSSON J, EMGARD M, ROSENBLAD C, BRUNDIN P: Treatment with the spin-trap agent a-phenyl-N-tert-butyl nitrone does not enhance the survival of embryonic or adult dopamine neurons. Brain Res. (1998) 805:155–168.
   PubMed Web of Science ®Google Scholar
• FERGER B, TEISMANN P, EARL CD, KUSCHINSKY K, OERTEL WH: The Protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping. Pharmacol. Biochem. Behav. (2000) 65:425–431.
   PubMed Web of Science ®Google Scholar
• LEVITES Y, WEINREB 0, MAOR G, YOUDIM MB, MANDEL S: Green tea polyphenol 0-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.j Neurochem. (2001) 78:1073–1082.
   PubMed Web of Science ®Google Scholar
• DATLA KP, CHRISTIDOU M, WIDMER WW, ROOPRAI HK, DEXTER DT: Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport (2001) 12:3871–3875.
   PubMed Web of Science ®Google Scholar
• SHAW KM, STERN GM, SANDLER M: Melatonin and parkinsonism. Lancet (1973) 1:271.
   PubMed Web of Science ®Google Scholar
• ACUNA-CASTROVIEJO D, COTO-MONTES A, GAIA MONTI M, ORTIZ GG, REITERMelatonin is protectiveagainst MPTP-induced striatal and hippocampal lesions. Life Sci. (1997) 60:PL23–29.
   PubMed Web of Science ®Google Scholar
• ORTIZ GG, CRESPO-LOPEZ ME, MORAN-MOGUEL C, GARCIA JJ, REITER RJ, ACUNA-CASTROVIEJO D: Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol. Lett. (2001) 22:101–108.
   PubMed Web of Science ®Google Scholar
• DABBENI-SALA F, DI SANTO S, FRANCESCHINI D, SKAPER SD, GIUSTI P: Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB (2001) 15:164–170.
   PubMed Web of Science ®Google Scholar
• MORGAN WW, NELSON JF: Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res. (2001) 921:115–121.
   PubMed Web of Science ®Google Scholar
• WILLIS GL, ARMSTRONG SM: A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. (1999) 66:785–795.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, YASOJIMA K, MCGEER EG: Inflammation in Parkinson's disease. Adv. Neurol. (2001) 86:83–89.
   PubMed Web of Science ®Google Scholar
• KURKOWSKA-JASTRZEBSKA I, WRONSKA A, KOHUTNICKA M, CZLONKOWSKI A, CZLONKOWSKA A: The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. (1999) 156:50–61.
   PubMed Web of Science ®Google Scholar
• FERGER B, TEISMANN P, EARL CD, KUSCHINSKY K, OERTEL WH: Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 360:256–261.
   PubMed Web of Science ®Google Scholar
• TEISMANN P, FERGER B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 39:167–174.
   PubMed Web of Science ®Google Scholar
• PASINETTI GM: Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. Neurosci. Res. (1998) 54:1–6.
   Web of Science ®Google Scholar
• CHASE TN: Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology(1998) 50(5 Suppl. 5):S17–23.
   Google Scholar
• GRUNBLATT E, MANDEL S, MAOR G, YOUDIM MB: Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. Neurochem. (2001) 77:146–156.
   PubMed Web of Science ®Google Scholar
• FORNAI F, BATTAGLIA G, GESI M, ORZI F, NICOLETTI F, RUGGIERI S: Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. (2001) 898:27–35.
   PubMed Web of Science ®Google Scholar
• DOS SANTOS EL-BACHA R, DAVAL J, KOZIEL V, NETTER P, MINN A: Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem. Pharmacol (2001) 61:73–85.
   PubMed Web of Science ®Google Scholar
• MURALIKRISHNAN D, EBADI M: SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. (2001) 892:241–247.
   PubMed Web of Science ®Google Scholar
• IIDA M, MIYAZAKI I, TANAKA K, KABUTO H, IWATA-ICHIKAWA E, OGAWA N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. (1999) 838:51–59.
   PubMed Web of Science ®Google Scholar
• BOZZI Y, VALLONE D, BORRELLI E: Neuroprotective role of dopamine against hippocampal cell death. j. Neurosci. (2000) 20:8643–8649.
   PubMed Web of Science ®Google Scholar
• CEPEDA C, HURST RS, ALTEMUS KL et al.: Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. j. Neurophysiol (2001) 85:659–670.
   PubMed Web of Science ®Google Scholar
• ANDERSON DW, NEAVIN T, SMITH JA, SCHNEIDER JS: Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res. (2001) 905:44–53.
   PubMed Web of Science ®Google Scholar
• ISHIGE K, CHEN Q, SAGARA Y, SCHUBERT D: The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. Neurosci. (2001) 21:6069–6076.
   PubMed Web of Science ®Google Scholar
• VONSATTEL JP, DIFIGLIA M: Huntington's disease. Neuropathol Exp. Neurol (1998) 57:369–384.
   PubMed Web of Science ®Google Scholar
• SCHERZINGER E, LURZ R, TURMAINE M et al.: Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 90:549–558.
   PubMed Web of Science ®Google Scholar
• DIFIGLIA M, SAPP E, CHASE KO et al: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 277:1990–1993.
   PubMed Web of Science ®Google Scholar
• PERUTZ MF: Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. (1999) 24:58–63.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO A, LUCAS JJ, HEN R: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 101:57–66.
   PubMed Web of Science ®Google Scholar
• NUCIFORA FC, SASAKI M, PETERS MF et al.: Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 291:2423–2428.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B, BEHL C: Mechanisms of neurodegenerative disorders: Part 1: Protein Aggregates. Arch. Neurol (2000) 57:793–796.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B, BEHL C: Mechanisms of neurodegenerative disorders: Part 2: Control of cell death. Arch. Neurol (2000) 57:801–804.
   PubMed Web of Science ®Google Scholar
• GUSELLA JF, MACDONALD ME: Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. (2001) 1:109–115.
   Web of Science ®Google Scholar
• HUNTINGTON STUDY GROUP: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397–404.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial.
   Google Scholar
• HUNTINGTON STUDY GROUP: Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology (1998) 50:1366–1373.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of a simple phenolic anti-oxidant with better BBB permeation.
   Google Scholar
• BLANCHET PJ, KONITSIOTIS S, HYLAND K, ARNOLD LA, PETTIGREW KD, CHASE TN: Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp. Neurol (1998) 153:214–222.
   PubMed Web of Science ®Google Scholar
• ABE K, MORITA S, KIKUCHI T, ITOYAMA Y: Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease. J. Neurosci. Res. (1997) 48:63–70.
   PubMed Web of Science ®Google Scholar
• PEYSER CE, FOLSTEIN M, CHASE GA et al.: Trial of D-a-tocopherol in Huntington's disease. Am. I Psychiatry (1995) 152:1771–1775.
   PubMed Web of Science ®Google Scholar
• BROUILLET E, CONDE F, BEAL MF, HANTRAYE P: Replicating Huntington's disease phenotype in experimental animals. Frog. Neurobiol (1999) 59:427–468.
   Google Scholar
• BROUILLET E, JENKINS BG, HYMAN BT et al.: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. Neurochem. (1993) 60:356–359.
   PubMed Web of Science ®Google Scholar
• LA FONTAINE MA, GEDDES JW, BANKS A, BUTTERFIELD DA: 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res. (2000) 858:356–362.
   PubMed Web of Science ®Google Scholar
• MATTHEWS RT, YANG L, JENKINS BG et al.: Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. j. Neurosci. (1998) 18:156-163. SHEAR DA, HAIK KL, DUNBAR GL: Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport (2000) 11:1833-1837. ANDREASSEN OA, FERRANTE RJ, DEDEOGLU A, BEAL MF: Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport (2001) 12:3371–3373.
   Google Scholar
• NAKAO N, BRUNDIN P: Effects of a-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience (1997) 76:749–761.
   PubMed Web of Science ®Google Scholar
• BINIENDA Z, JOHNSON JR, TYLER-HASHEMI AA et al.: Protective effect of L-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA). Ann. NY Acad. Sci. (1999) 890:173–178.
   PubMed Web of Science ®Google Scholar
• GRAMSBERGEN JB, SANDBERG M, KORNBLIT B, ZIMMER J: Pyruvate protects against 3-nitropropionic acid induced neurotoxicity in corticostriatal slice cultures. Neuroreport (2000) 11:2743–2747.
   PubMed Web of Science ®Google Scholar
• KASHIWAYA Y, TAKESHIMA T, MORI N, NAKASHIMA K, CLARKE K, VEECH RL: D-P-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's
   Google Scholar
• ALAM ZI, HALLIWELL B, JENNER P: No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. Neurochem. (2000) 75:840-846.281.
   Google Scholar
• KOROSHETZ WJ, JENKINS BG, ROSEN BR, BEAL MF: Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol (1997) 41:160-165.282.
   PubMed Web of Science ®Google Scholar
• FEIGIN A, KIEBURTZ K, COMO P et al.: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. (1996) 11:321-323.283.
   PubMed Web of Science ®Google Scholar
• RANEN NG, PEYSER CE, COYLE JT et al.: A controlled trial of idebenone in Huntington's disease. Mov. Disord. (1996) 11:549-554. disease. Proc. Natl. Acad. Sci. USA (2000) 97:5440–5444.
   Google Scholar
• VEECH RL, CHANCE B, KASHIWAYA Y, LARDY HA, CAHILL GF: Ketone bodies, potential therapeutic uses. IUBMB Life (2001) 51:241–247.
   PubMed Web of Science ®Google Scholar
• RIVAS-ARANCIBIA S, RODRIGUEZ Al, ZIGOVA T et al: Taurine increases rat survival and reduces striatal damage caused by 3-nitropropionic acid. Int. .1. Neurosci. (2001) 108:55–67.
   PubMed Web of Science ®Google Scholar
• ARUOMA OI, HALLIWELL B, HOEY BM, BUTLER J: The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J. (1988) 256:251–255.
   PubMed Web of Science ®Google Scholar
• RODRIGUES CM, STIEERS CL, KEENE CD et al: Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. Neurochem. (2000) 75:2368–2379.
   PubMed Web of Science ®Google Scholar
• HELLER-STILB B, VAN ROEYEN C, RASCHER K et al.: Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB (2001) 15:42–59.
   Web of Science ®Google Scholar
• ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in Cu! Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
   PubMed Web of Science ®Google Scholar
• AL-CHALABI A, LEIGH PN: Recent advances in amyotrophic lateral sclerosis. Curt: Opin. Neurol. (2000) 13:397–405.
   PubMedGoogle Scholar
• VINCETI M, NACCI G, ROCCHI E et al.: Mortality in a population with long-term exposure to inorganic selenium via drinking water. J. Clin. Epidennol. (2000) 53:1062–1068.
   PubMed Web of Science ®Google Scholar
• NELSON LM, MATKIN C, LONGSTRETH WT, MCGUIRE V: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am. J. Epidennol. (2000) 151:164–173.
   PubMed Web of Science ®Google Scholar
• NELSON LM, MCGUIRE V, LONGSTRETH WT, MATKIN C: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am. J. Epidemiol. (2000) 151:156–163.
   Google Scholar
• GURNEY ME: Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. (1997) 244\(Suppl. 2):515–520.
   Google Scholar
• BRUIJN LI, BEAL ME BECHER MW et al.: Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. USA (1997) 94:7606–7611.
   Google Scholar
• GURNEY ME: What transgenic mice tell us about neurodegenerative disease. Bioessays (2000) 22:297–304.
   PubMed Web of Science ®Google Scholar
• LEE M, HYUN D, JENNER P, HALLIWELL B: Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis.' Neurochem. (2001) 76:957–965.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JA, DALTON MJ, GURNEY ME, KOPITO RR: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Nati Acad. St". USA (2000) 97:12571–12576.
   PubMed Web of Science ®Google Scholar
• SHAW PJ, EGGETT CJ: Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J. Neurol. (2000) 247\(Suppl. 1):I17–I27.
   Google Scholar
• PARKES TL, ELIA AJ, DICKINSON D, HILLIKER AJ, PHILLIPS JP, BOULIANNE GL: Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurones. Nat. Genetics (1998) 19:171–174.
   PubMed Web of Science ®Google Scholar
• JUNG C, RONG Y, DOCTROW S, BAUDRY M, MALFROY B, XU Z: Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. (2001) 304:157–160.
   PubMed Web of Science ®Google Scholar
• PODUSLO JF, WHELAN SL, CURRAN GL, WENGENACK TM: Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. Ann. Neurol. (2000) 48:943–947.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. (1996) 39:147–157.
   PubMed Web of Science ®Google Scholar
• DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo- controlled randomized clinical trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord (2001) 2:9–18.
   PubMed Web of Science ®Google Scholar
• •Clinical trial.
   Google Scholar
• KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5:347–350.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN OA, JENKINS BG, DEDEOGLU A et al.: Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. (2001) 77:383–390.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN OA, DEDEOGLU A, FRIEDLICH A et al.: Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. (2001) 168:419–424.
   PubMed Web of Science ®Google Scholar
• NAGANO S, OGAWA Y, YANAGIHARA T, SAKODA S: Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci. Lett. (1999) 265:159–162.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN OA, DEDEOGLU A, KLIVENYI P, BEAL MF, BUSH Al: N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport (2000) 11:2491–2493.
   PubMed Web of Science ®Google Scholar
• JAARSMA D, GUCHELAAR HJ, HAASDIJK E, DE JONG JM, HOLSTEGE JC: The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. Ann. Neurol. (1998) 44:293.
   PubMed Web of Science ®Google Scholar
• HENDERSON JT, JAVAHERI M, KOPKO S, RODER JC: Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. Neurosci. (1996) 16:7574–7582.
   PubMed Web of Science ®Google Scholar
• LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol. (1995) 52:559–564.
   PubMed Web of Science ®Google Scholar
• •Clinical trial, reporting the inefficiency of N-acetylcysteine in ALS.
   Google Scholar
• VYTH A, TIMMER JG, BOSSUYT PM, LOUWERSE ES, DE JONG JM: Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J. Neurol. Sci. (1996) 139(Suppl.):99–103.
   Google Scholar
• •Interesting small-scale trial, but with a negative outcome.
   Google Scholar
• CUDKOWICZ ME, SEXTON PM, ELLIS T et al.: The pharmacokinetics and pharmacodynamics of procysteine in amyotrophic lateral sclerosis. Neurology (1999) 52:1492–1494.
   PubMed Web of Science ®Google Scholar
• LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol. (1998) 55:93–96.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial.
   Google Scholar
• FISCHER H, GOTTSCHLICH R, SEELIG A: Blood-brain barrier permeation: molecular parameters governing passive diffusion. I Membrane Bra (1998) 165:201–211.
   Web of Science ®Google Scholar
• MOOSMANN B, BEHL C: Cytoprotective antioxidant function of tyrosine and tryptophan residues in transmembrane proteins. Eur. Biochem. (2000) 267:5687–5692.
   PubMedGoogle Scholar
• MOOSMANN B, BEHL C: Dietary phenols: antioxidants for the brain? Num Neurosci. (2000) 3:1–10.
   Google Scholar
• ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and I3-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. Med. (1994) 330:1029–1035.
   PubMed Web of Science ®Google Scholar
• ROWE PM: 3-Carotene takes a collective beating. Lancet (1996) 347:249.
   PubMed Web of Science ®Google Scholar
• AMES BN, GOLD LS: The prevention of cancer. Drug Metab. Rev (1998) 30:201–223.
   PubMed Web of Science ®Google Scholar
• MASAKI KH, LOSONCZY KG, IZMIRLIAN G et al.: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology (2000) 54:1265–1272.
   PubMed Web of Science ®Google Scholar
• DESCHAMPS V, BARBERGER- GATEAU P, PEUCHANT E, ORGOGOZO JM: Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. Neuroepidemiology (2001) 20:7–15.
   PubMed Web of Science ®Google Scholar
• CANTUTI-CASTELVETRI I, SHUKITT-HALE B, JOSEPH JA: Neurobehavioural aspects of antioxidants in aging. Int. Dev. Neurosci (2000) 18:367–381.
   PubMed Web of Science ®Google Scholar
• HALLIWELL B: Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic. Res. (1996) 25:57–74.
   Google Scholar
• HALLIWELL B: The antioxidant paradox.
   Google Scholar
• LANGSTON JW, FORNO LS, TETRUD J, REEVES AG, KAPLAN JA, KARLUK D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. (1999) 46:598–605.
   PubMed Web of Science ®Google Scholar
• VINGERHOETS FJ, SNOW BJ, TETRUD JW, LANGSTON JW, SCHULZER M, CALNE DB: Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. (1994) 36:765–770.
   PubMed Web of Science ®Google Scholar
• ROSENOW F, HERHOLZ K, LANFERMANN H et al.: Neurological sequelae of cyanide intoxication - the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. Ann. Neurol. (1995) 38:825–828.
   PubMed Web of Science ®Google Scholar
• HUANG CC, LU CS, CHU NS et al.: Progression after chronic manganese exposure. Neurology (1993) 43:1479–1483.
   PubMed Web of Science ®Google Scholar
• LYE TC, SHORES EA: Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychoi Rev (2000) 10:115–129.
   PubMed Web of Science ®Google Scholar
• CLARKE G, COLLINS RA, LEAVITT BR et al.: A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 406:195–199.
   PubMed Web of Science ®Google Scholar
• CLARKE G, LUMSDEN CJ, MCINNES RR: Inherited neurodegenerative diseases: the one-hit model of neurodegeneration. Hum. MM. Genet. (2001) 10:2269–2275.
   PubMed Web of Science ®Google Scholar
• PRESTERA T, TALALAY P: Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc. Nati Acad. Sci. USA (1995) 92:8965–8969.
   PubMed Web of Science ®Google Scholar
• PRESTERA T, ZHANG Y, SPENCER SR, WILCZAK CA, TALALAY P: The electrophile counterattack response: protection against neoplasia and toxicity. Adv Enzyme Regui (1993) 33:281–296.
   PubMedGoogle Scholar
• AMES BN, GOLD LS: Misconceptions on pollution and the causes of cancer. Angew. Chem. Int. Ed. (1990) 29:1197–1208.
   Web of Science ®Google Scholar
• GOLD LS, SLONE TH, AMES BN: What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab. Rev (1998) 30:359–404.
   PubMed Web of Science ®Google Scholar
• FIANDER H, SCHNEIDER H: Compounds that induce isoforms of lutathione S-transferase with properties of a critical enzyme in defense against oxidative stress. Biochem. Biophys. Res. Commun. (1999) 262:591–595.
   PubMed Web of Science ®Google Scholar
• ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. (1991) 11:81–128.
   PubMed Web of Science ®Google Scholar
• SAYRE LM, ZELASKO DA, HARRIS PL, PERRY G, SALOMON RG, SMITH MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Neurochem. (1997) 68:2092–2097.
   PubMed Web of Science ®Google Scholar
• CALINGASAN NY, UCHIDA K, GIBSON GE: Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. Neurochem. (1999) 72:751–756.
   PubMed Web of Science ®Google Scholar
• LOVELL MA, EHMANN WD, BUTLER SM, MARKESBERY WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's diesease. Neurology (1995) 45:1594–1601.
   PubMed Web of Science ®Google Scholar
• YAN SD, CHEN X, SCHMIDT AM et al.: Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc. Nati Acad. Sri. USA (1994) 91:7787–7791.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, SMITH MA, AVILA J et al.: In Alzheimer's disease, heme oxygenase is
   Google Scholar
• GILGUN-SHERKI Y, MELAMED E,studies on tocopherol in coronary heart disease.
   Google Scholar
• GILGUN-SHERKI Y, MELAMED E,sumies on Locopnerm m coronary nearL OFFEN D: Oxidative stress-induceddisease. neurodegenerative diseases: the need for333. TALALAY P, TALALAY P: The importance antioxidants that penetrate the blood-brainof using scientific principles in the barrier. Neuropharmacology (2001) 40:959-development of medicinal agents from 975.plants. Acad. Med. (2001) 76:238–247.
   Google Scholar
• MOOSMANN B, SKUTELLA T, BEYERLancet (2000) 335:1179-1180. K, BEHL C: Protective activity of aromatic•An essay highlighting the fact that anti- amines and imines against oxidative nerveoxidant action and reduction potential are cell death. Biol. Chem. (2001) 382:1601-very unequal properties in biological 1612.systems. Also discusses some recent clinical coincident with A1z50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. (2000) 75:1234–1241.
   Google Scholar
• LOSKE C, GERDEMANN A, SCHEPL W et al.: Transition metal-mediated glycoxidation accelerates cross-linking of 13-amyloid peptide. Eur: j Biochem. (2000) 267:4171–4178.
   PubMedGoogle Scholar
• KRUMAN I, BRUCE-KELLER AJ, BREDESEN D, WAEG G, MATTSON MP: Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. j Neurosci. (1997) 17:5089–5100.
   PubMed Web of Science ®Google Scholar
• XIE C, LOVELL MA, MARKESBERY WR: Glutathione transferase protects neuronal cultures against 4-hydroxynonenal toxicity. Free Radic. Biol. Med. (1998) 25:979–988.
   PubMed Web of Science ®Google Scholar
• GAO X, DINKOVA-KOSTOVA AT, TALALAY P: Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA (2001) 98:15221–15226.
   PubMed Web of Science ®Google Scholar
• •Shows the inducibility of an anti-electrophile response (in proliferating cells) by a nutritional (broccoli) inducer.
   Google Scholar
• FIANDER H, SCHNEIDER H: Dietary ortho-phenols that induce glutathione 5-transferase and increase the resistance of cells to hydrogen peroxide are potential cancer chemopreventives that act by two mechanisms: the alleviation of oxidative stress and the detoxification of mutagenic xenobiotics. Cancer Lett. (2000) 156:117–124.
   PubMed Web of Science ®Google Scholar
• HUBATSCH I, RIDDERSTROM M, MANNERVIK B: Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid perwddation. Biochem. (1998) 330:175–179.
   Web of Science ®Google Scholar
• BEHL C: Apoptosis and Alzheimer's disease. J. Neural Transm. (2000) 107:1325–1344.
   PubMed Web of Science ®Google Scholar
• MATTSON M: Apoptosis in neurodegenerative disorders. Nat. Rev. Ma Cell Biol. (2000) 1:120–129.
   PubMed Web of Science ®Google Scholar
• RAINA AK, HOCHMAN A, ZHU X et al.: Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (2001) 101:305–310.
   PubMed Web of Science ®Google Scholar
• •An interesting study, claiming a form of throttled apoptosis in AD.
   Google Scholar
• ISHIGE K, SCHUBERT D, SAGARA Y: Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med. (2001) 30:433–446.
   PubMed Web of Science ®Google Scholar
• CHOI JA, KIM JY, LEE JY et al.: Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol (2001) 19:837–844.
   PubMed Web of Science ®Google Scholar
• WENZEL U, KUNTZ S, BRENDEL MD, DANIEL H: Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res. (2000) 60:3823–3831.
   PubMed Web of Science ®Google Scholar
• LINFORD NJ, YANG Y, COOK DG, DORSA DM: Neuronal apoptosis resulting from high doses of the isoflavone genistein: role for calcium and p42/44 mitogen-activated protein kinase. j Pharmacol Exp. The]: (2001) 299:67–75.
   Google Scholar
• GALATI G, TENG S, MORIDANI MY, CHAN TS, O'BRIEN PJ: Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metab. Drug Interact. (2000) 17:311–349.
   PubMedGoogle Scholar
• KLATT P, MOLINA EP, DE LACOBA MG et al.: Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J. (1999) 13:1481–1490.
   Google Scholar
• COTGREAVE IA, GERDES RG: Recent trends in glutathione biochemistry - glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? Biochem. Biophys. Res. Commun. (1998) 242:1–9.
   PubMed Web of Science ®Google Scholar
• SIAN J, DEXTER DT, LEES AJ et al: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol (1994) 36:348–355.
   PubMed Web of Science ®Google Scholar
• OWEN AD, SCHAPIRA AH, JENNER P, MARSDEN CD: Oxidative stress and Parkinson's disease. Ann. NY Acad. Sci. (1996) 786:217–223.
   PubMed Web of Science ®Google Scholar
• OLNEY JW, ZORUMSKI C, PRICE MT, LABRUYERE J: L-cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science (1990) 248:596–599.
   PubMed Web of Science ®Google Scholar
• YEH MW, KAUL M, ZHENG J et al: Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of L-cysteine. Immunol (2000) 164:4265–4270.
   Web of Science ®Google Scholar
• GUTZMANN H, KUHL KP, HADLER D, RAPP MA: Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry(2002) 35:12–18.
   PubMed Web of Science ®Google Scholar
• SHOULSON I, OAKES D, FAHN S et al: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol (2002) 51:604–612.
   PubMed Web of Science ®Google Scholar